

## Supplementary Materials

<b>Supplementary appendix 1 Participating centres including study teams</b>			
<b>Centre</b>	<b>Principle Investigator (and Associated Investigators)</b>	<b>Nurses</b>	<b>Supervisors</b>
Amsterdam Medical Center	Henrike Westerveld	Wilma van der Ham-Paalman Sandra Diergaarde Wendy Lesterhuis	Ellen Laan† Hanneke Termeer
Catharina Hospital	Jeltsje Cnossen Hetty van den Berg	Noor Vincent Ivonne Oomen	Rian Brus Simone Speelman
Erasmus Medical Center	Jan Willem Mens Helena van Doorn Remi Nout	Claudia Mangelaars Karin Dupree Nicoline Schuur – van 't Hof Sabine Blom Christel de Jager-Blom	Hanneke Bolt
Leiden University Medical Center	Carien Creutzberg Cor de Kroon Laura Velema	Corine de Jong Mirjam Laman	Charlotte Tuijnman-Raasveld Ellen de Groot
Maastrou	Ludy Lutgens	Moniek Kamps Charlotte Penders	Reinhilde Melles
Netherlands Cancer Institute	Marlies Nowee	Kirsten de Greef Erin Gardebroek-de Boer	Ilaniek Zantingh
Radboud University Medical Center	An Snyers	Annemieke Janssens Lotte Knapen	Marianne Vergeer
Radiotherapiegroep	Dorien Haverkort	Janine de Neeff Truus Kroeze	Irma Bosman
University Medical Center Groningen	Jannet Beukema	Bianca Kramer-Medema Nina van Linde	Ria Bosgraaf
University Medical Center Utrecht	Ina Jurgenliemk-Schulz	Nicole van den Berg Catharina van der Linden-Hunziker Ankie Krol Veraar	Ilaniek Zantingh

**Supplementary appendix 2 Additional patient and physician-reported outcomes**

Variable	Questionnaire	Clinical cut-off score
Sexual functioning	FSFI	≤26-55
Sexual desire	FSFI	NA
Sexual arousal	FSFI	NA
Vaginal lubrication	FSFI	NA
Orgasmic function	FSFI	NA
Sexual satisfaction	FSFI	NA
Sexual pain	FSFI	NA
Sexual distress	FSDS	≥15
Symptom experience	EORTC QLQ-CX24	NA
Body image	EORTC QLQ-CX24/QLQ-EN24	NA
Sexual/vaginal functioning (dryness, shortness, tightness, pain during intercourse)	EORTC QLQ-CX24/QLQ-EN24	NA
Vaginal tightness	EORTC QLQ-CX24/QLQ-EN24	NA
Lymphedema	EORTC QLQ-CX24/QLQ-EN24	NA
Peripheral neuropathy	EORTC QLQ-CX24	NA
Menopausal symptoms	EORTC QLQ-CX24	NA
Sexual worry	EORTC QLQ-CX24	NA
Sexual activity	EORTC QLQ-CX24/QLQ-EN24	NA
Sexual enjoyment	EORTC QLQ-CX24/QLQ-EN24	NA
Urological symptoms	EORTC QLQ-EN24	NA
Gastrointestinal symptoms	EORTC QLQ-EN24/QLQ-EN24	NA
Sexual interest	EORTC QLQ-EN24	NA
Fear of non-penetration sexual activity	FSQ	NA
Fear of coitus/vaginal penetration	FSQ	NA
Relationship dissatisfaction	MMQ	≥20
Psychological distress	HADS	≥14
Depression	HADS	≥7
Anxiety	HADS	≥7
Physical function	EORTC QLQ-C30	NA
Role function	EORTC QLQ-C30	NA
Emotional function	EORTC QLQ-C30	NA
Cognitive function	EORTC QLQ-C30	NA
Social function	EORTC QLQ-C30	NA
Fatigue	EORTC QLQ-C30	NA
Nausea/vomiting	EORTC QLQ-C30	NA
Pain	EORTC QLQ-C30	NA
Dyspnoea	EORTC QLQ-C30	NA
Sleep disturbance	EORTC QLQ-C30	NA
Appetite loss	EORTC QLQ-C30	NA
Constipation	EORTC QLQ-C30	NA
Diarrhoea	EORTC QLQ-C30	NA
Financial impact	EORTC QLQ-C30	NA
Global QoL	EORTC QLQ-C30	NA
Treatment related stress – intrusion	IES	NA
Treatment related stress – avoidance	IES	NA
Cost-effectiveness		
Sexual health care use	-	NA
Quality of life	EQ-5D-5L	NA
Credibility of analogue therapy rationales	CEQ	NA
Physician-reported Bleeding	CTCAE	≥grade 3 = severe
Physician-reported Mucositis	CTCAE	≥grade 3 = severe
Physician-reported Discharge	CTCAE	≥grade 3 = severe
Physician-reported Fibrosis	CTCAE	≥grade 3 = severe
Physician-reported Atrophy/telangiectasia	CTCAE	≥grade 3 = severe
Physician-reported Pain	CTCAE	≥grade 3 = severe
Physician-reported Dyspareunia	CTCAE	≥grade 3 = severe
Physician-reported vaginal estradiol/estriol	CRF	NA
Physician-reported hormone replacement therapy	CRF	NA

*Note.* CEQ = Credibility/Expectancy Questionnaire; CRF = Case Report Form; CTCAE = Common Terminology Criteria for Adverse Events; EORTC QLQ-C30 = European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30; EORTC QLQ-CX24 = European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gynaecological Cancer Module; EORTC QLQ-EN24 = European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Endometrial Cancer Module; EQ-5D-5L = EuroQol 5D-5L; FSDS = Female Sexual Distress Scale; FSFI = Female Sexual Function Index; FSQ = Fear of Sexuality Questionnaire; HADS = Hospital Anxiety and Depression Scale; IES = Impact of Event Scale; MMQ = Maudsley Marital Questionnaire; NA = not applicable

**Supplementary appendix 3 Total and subscale mean values at retrospective baseline (for FSFI and FSDS) 1, 3, 6 and 12 months after radiotherapy and GLMM likelihood ratio test outcomes of primary and secondary continuous outcome measures**

Outcome measure (range score)	Assessment												GLMM outcomes					
	T1			T2			T3			T4			T5			LRT(df)	P (overall model)	
	N	M/ %	SD	N	M/ %	SD	N	M/ %	SD	N	M/ %	SD	N	M/ %	SD			
<b>Primary</b>																		
Sexual functioning																		
FSFI total (2-36)																	10-88(10)	0-37
Intervention	112	28.08	6.48	108	18.36	10.27	106	21.98	9.45	98	23.82	8.83	94	22.57	9.30			
Care-as-usual	117	28.30	7.07	110	17.38	10.64	106	22.26	9.10	98	22.89	8.74	87	21.76	10.42			
Sexual desire																		
FSFI sexual desire (1-2-6)																	7.59(10)	0.67
Intervention	112	3.81	0.99	108	2.92	1.25	106	3.05	1.27	99	3.31	1.30	94	2.99	1.32			
Care-as-usual	117	3.76	0.99	110	2.80	1.24	106	2.99	1.23	98	3.04	1.18	88	3.08	1.34			
Sexual arousal																		
FSFI arousal (0-6)																	13.16(10)	0.21
Intervention	112	4.75	1.40	108	2.93	2.09	106	3.63	1.95	98	3.90	1.89	94	3.52	1.98			
Care-as-usual	117	4.81	1.35	110	2.72	2.31	106	3.67	1.90	98	3.75	1.91	88	3.69	2.07			
Vaginal lubrication																		
FSFI lubrication (0-6)																	4.06(10)	0.95
Intervention	112	5.14	1.49	108	3.10	2.43	106	3.76	2.19	98	4.15	2.11	94	3.88	2.23			
Care-as-usual	117	5.24	1.52	110	2.89	2.52	106	3.93	2.14	98	4.17	2.13	88	3.80	2.40			
Orgasmic function																		
FSFI orgasm (0-6)																	6.52(10)	0.77
Intervention	112	4.80	1.32	108	3.15	2.35	106	3.88	2.10	98	4.05	1.91	94	3.95	1.98			
Care-as-usual	117	4.97	1.54	110	2.98	2.49	106	4.03	2.11	98	4.19	2.11	88	3.84	2.32			
Sexual satisfaction																		
FSFI satisfaction (0-6)																	1.49(10)	0.99
Intervention	112	4.88	1.19	108	3.77	1.54	106	4.11	1.59	98	4.40	1.35	94	4.18	1.53			
Care-as-usual	117	4.77	1.36	110	3.62	1.58	106	4.11	1.52	98	4.20	1.49	87	4.06	1.54			
Sexual pain																		
FSFI pain (0-6)																	10.75(10)	0.37
Intervention	112	4.70	1.82	108	2.49	2.52	106	3.54	2.28	98	4.02	2.08	94	4.03	2.25			
Care-as-usual	117	4.75	1.89	110	2.37	2.45	106	3.54	2.28	98	3.54	2.18	87	3.38	2.52			

**Supplementary appendix 3** *Continued*

Outcome measure (range score)	Assessment															GLMM outcomes					
	T1			T2			T3			T4			T5			LRT(df)	P (overall model)				
	N	M/%	SD	N	M/%	SD	N	M/%	SD	N	M/%	SD	N	M/%	SD						
<b>Sexual activity</b>																					
<b>Intervention</b>																					
<i>Never</i>	20	18.0	..	45	41.7	..	36	34.0	..	34	34.7	..	27	28.7	..	0.54(5)	0.99				
<i>Several times per month</i>	33	29.7	..	26	24.1	..	32	30.2	..	29	29.6	..	36	38.3	..						
<i>1 time/week</i>	20	18.0	..	17	15.7	..	17	16.0	..	16	16.3	..	15	16.0	..						
<i>≥2 times/week</i>	38	34.2	..	20	18.5	..	21	19.8	..	19	19.4	..	16	17.0	..						
<b>Care-as-usual</b>																					
<i>Never</i>	22	19.0	..	45	40.9	..	37	34.9	..	34	34.7	..	27	31.0	..	3.36(3)	0.34				
<i>Several times per month</i>	37	31.9	..	28	25.5	..	34	32.1	..	37	37.8	..	37	42.5	..						
<i>1 time/week</i>	28	24.1	..	11	10.0	..	16	15.1	..	11	11.2	..	11	12.6	..						
<i>≥2 times/week</i>	29	25.0	..	26	23.6	..	19	17.9	..	16	16.3	..	12	13.8	..						
<b>Sexual Intercourse</b>																					
<b>Intervention</b>																					
<i>Never</i>	15	13.6	..	62	57.9	..	37	34.9	..	25	25.5	..	29	30.9	..	7.57(10)	0.67				
<i>Several times per month</i>	33	30.0	..	19	17.8	..	24	22.6	..	28	28.6	..	22	23.4	..						
<i>1 time/week</i>	18	16.4	..	14	13.1	..	22	20.8	..	20	20.4	..	26	27.7	..						
<i>≥2 times/week</i>	44	40.0	..	12	11.2	..	23	21.7	..	25	25.5	..	17	18.1	..						
<b>Care-as-usual</b>																					
<i>Never</i>	20	17.1	..	71	64.5	..	37	34.9	..	37	37.8	..	31	35.6	..	94	14.65				
<i>Several times per month</i>	37	31.6	..	13	11.8	..	32	30.2	..	26	26.5	..	25	28.7	..			87	13.94		
<i>1 time/week</i>	25	21.4	..	7	6.4	..	17	16.0	..	13	13.3	..	13	14.9	..					12.07	10.97
<i>≥2 times/week</i>	35	29.9	..	19	17.3	..	20	18.9	..	22	22.4	..	18	20.7	..						
<b>Secondary</b>																					
<b>Sexual Distress</b>																					
<b>FSDS (0-48)</b>																					
<i>Intervention</i>	112	9.32	9.40	107	14.37	10.49	106	13.69	10.55	98	14.17	10.31	94	14.65	12.07	7.57(10)	0.67				
<i>Care-as-usual</i>	117	8.74	9.36	110	12.95	10.01	106	13.17	9.92	98	14.35	11.36	87	13.94	10.97						

**Supplementary appendix 3** *Continued*

Outcome measure (range score)	Assessment															GLMM outcomes	
	T1			T2			T3			T4			T5			LRT(df)	P (overall model)
	N	M/%	SD	N	M/%	SD	N	M/%	SD	N	M/%	SD	N	M/%	SD		
Vaginal dilation																	
Dilator use																5.25(4)	0.24
Intervention																	
<i>Never</i>	..	..	..	43	45.3	..	8	8.6	..	14	16.3	..	22	26.8	..		
<i>Several times per month</i>	..	..	..	3	3.2	..	6	6.5	..	8	9.3	..	19	23.2	..		
<i>1 time/week</i>	..	..	..	5	5.3	..	12	12.9	..	20	23.3	..	15	18.3	..		
<i>2 times/week</i>	..	..	..	10	10.5	..	27	29.0	..	16	18.6	..	17	20.7	..		
<i>3 times/week</i>	..	..	..	29	30.5	..	38	40.9	..	25	29.1	..	9	11.0	..		
<i>4-6 times/week</i>	..	..	..	5	5.3	..	2	2.2	..	3	3.5	..	0	0	..		
<i>Daily</i>	..	..	..	0	0	..	0	0	..	0	0	..	0	0	..		
Care-as-usual																	
<i>Never</i>	..	..	..	40	43.0	..	17	18.7	..	23	27.1	..	29	38.2	..		
<i>Several times per month</i>	..	..	..	4	4.3	..	12	13.2	..	13	15.3	..	23	30.3	..		
<i>1 time/week</i>	..	..	..	5	5.4	..	9	9.9	..	19	22.4	..	6	7.9	..		
<i>2 times/week</i>	..	..	..	16	17.2	..	21	23.1	..	15	17.6	..	10	13.2	..		
<i>3 times/week</i>	..	..	..	25	26.9	..	29	31.9	..	13	15.3	..	6	7.9	..		
<i>4-6 times/week</i>	..	..	..	1	1.1	..	3	3.3	..	1	1.2	..	2	2.6	..		
<i>Daily</i>	..	..	..	2	2.2	..	0	0	..	1	1.2	..	0	0	..		
Vaginal dilation																	
Vibrator/dildo /fingers																1.90(4)	0.75
Intervention																	
<i>Never</i>	..	..	..	67	70.5	..	48	51.6	..	46	53.5	..	38	46.3	..		
<i>Several times per month</i>	..	..	..	12	12.6	..	25	26.9	..	21	24.4	..	28	34.1	..		
<i>1 time/week</i>	..	..	..	7	7.4	..	12	12.9	..	11	12.8	..	10	12.2	..		
<i>2 times/week</i>	..	..	..	4	4.2	..	6	6.5	..	6	7.0	..	2	2.4	..		
<i>3 times/week</i>	..	..	..	4	4.2	..	2	2.2	..	2	2.3	..	4	4.9	..		
<i>4-6 times/week</i>	..	..	..	1	1.1	..	0	0	..	0	0	..	0	0	..		
<i>Daily</i>	..	..	..	0	0	..	0	0	..	0	0	..	0	0	..		
Care-as-usual																	
<i>Never</i>	..	..	..	68	73.1	..	58	63.7	..	49	57.6	..	46	60.5	..		
<i>Several times per month</i>	..	..	..	12	12.9	..	21	23.1	..	23	27.1	..	19	25.0	..		
<i>1 time/week</i>	..	..	..	2	2.2	..	6	6.6	..	5	5.9	..	5	6.6	..		
<i>2 times/week</i>	..	..	..	7	7.5	..	2	2.2	..	2	2.4	..	5	6.6	..		
<i>3 times/week</i>	..	..	..	2	2.2	..	2	2.2	..	3	3.5	..	1	1.3	..		
<i>4-6 times/week</i>	..	..	..	1	1.1	..	1	1.1	..	2	2.4	..	0	0	..		
<i>Daily</i>	..	..	..	1	1.1	..	1	1.1	..	1	1.2	..	0	0	..		

**Supplementary appendix 3** *Continued*

Outcome measure (range score)	Assessment															GLMM outcomes	
	T1			T2			T3			T4			T5			LRT(df)	P (overall model)
	N	M/%	SD	N	M/%	SD	N	M/%	SD	N	M/%	SD	N	M/%	SD		
Vaginal dilation - Intercourse																	
Intervention	..	..	..	60	63.2	..	35	37.6	..	22	25.6	..	25	30.5	..	2.33(4)	0.68
<i>Never</i>	..	..	..	10	10.5	..	18	19.4	..	24	27.9	..	18	22.0	..		
<i>Several times per month</i>	..	..	..	14	14.7	..	21	22.6	..	16	18.6	..	23	28.0	..		
<i>1 time/week</i>	..	..	..	9	9.5	..	13	14.0	..	16	18.6	..	11	13.4	..		
<i>2 times/week</i>	..	..	..	2	2.1	..	5	5.4	..	6	7.0	..	3	3.7	..		
<i>3 times/week</i>	..	..	..	0	0	..	0	0	..	1	1.2	..	2	2.4	..		
<i>4-6 times/week</i>	..	..	..	0	0	..	1	1.1	..	1	1.2	..	0	0	..		
<i>Daily</i>	..	..	..	62	66.7	..	34	37.4	..	32	37.6	..	26	34.2	..		
Care-as-usual	..	..	..	12	12.9	..	27	29.7	..	28	32.9	..	23	30.3	..		
<i>Never</i>	..	..	..	5	5.4	..	12	13.2	..	9	10.6	..	12	15.8	..		
<i>Several times per month</i>	..	..	..	6	6.5	..	9	9.9	..	10	11.8	..	8	10.5	..		
<i>1 time/week</i>	..	..	..	5	5.4	..	6	6.6	..	4	4.7	..	3	3.9	..		
<i>2 times/week</i>	..	..	..	2	2.2	..	2	2.2	..	1	1.2	..	3	3.9	..		
<i>3 times/week</i>	..	..	..	1	1.1	..	1	1.1	..	1	1.2	..	1	1.3	..		
<i>4-6 times/week</i>	..	..	..	1	1.1	..	1	1.1	..	1	1.2	..	1	1.3	..		
<i>Daily</i>	..	..	..	1	1.1	..	1	1.1	..	1	1.2	..	1	1.3	..		
Any type of vaginal dilation ≥2 times/week																	
Intervention	..	..	..	66	69.5	..	90	96.8	..	81	94.2	..	70	85.4	..	1.39(4)	0.85
<i>Yes</i>	..	..	..	29	30.5	..	3	3.2	..	5	5.8	..	12	14.6	..		
<i>No</i>	..	..	..	60	64.5	..	82	90.1	..	69	81.2	..	57	75.0	..		
Care-as-usual	..	..	..	33	35.5	..	9	9.9	..	16	18.8	..	19	25.0	..		
<i>Yes</i>	..	..	..	60	64.5	..	82	90.1	..	69	81.2	..	57	75.0	..		
<i>No</i>	..	..	..	33	35.5	..	9	9.9	..	16	18.8	..	19	25.0	..		
Sexual functioning																	
EORTC QLQ-CX24 (0-100)																	
Intervention	..	..	..	52	26.44	19.65	76	22.59	20.18	77	21.43	18.75	70	18.69	19.32	10.64(8)	0.22
Care-as-usual	..	..	..	50	23.67	18.62	70	22.74	17.60	66	22.60	16.06	62	19.49	21.65		
Vaginal symptoms																	
EORTC QLQ-CX24 (0-100)																	
Intervention	..	..	..	107	16.30	14.90	106	11.43	11.83	98	11.0	12.71	94	10.99	13.19	3.92(8)	0.86
Care-as-usual	..	..	..	109	16.00	14.46	106	12.06	13.38	97	10.20	12.39	87	10.47	13.38		

**Supplementary appendix 3** *Continued*

Outcome measure (range score)	Assessment															GLMM outcomes		
	T1			T2			T3			T4			T5			LRT(df)	P (overall model)	
	N	M/%	SD	N	M/%	SD	N	M/%	SD	N	M/%	SD	N	M/%	SD			
Sexual/vaginal functioning EORTC QLQ-CX24 Vaginal dryness																		
Intervention																	0.83(8)	0.99
<i>Not at all</i>	..	..	..	20	38.5	..	35	46.1	..	35	45.5	..	36	51.4	..			
<i>A little</i>	..	..	..	25	48.1	..	22	28.9	..	27	35.1	..	19	27.1	..			
<i>Quite a bit</i>	..	..	..	5	9.6	..	11	14.5	..	12	15.6	..	11	15.7	..			
<i>Very much</i>	..	..	..	2	3.8	..	8	10.5	..	3	3.9	..	4	5.7	..			
Care-as-usual																		
<i>Not at all</i>	..	..	..	25	50.0	..	30	42.9	..	26	39.4	..	31	50.0	..			
<i>A little</i>	..	..	..	14	28.0	..	33	47.1	..	31	47.0	..	23	37.1	..			
<i>Quite a bit</i>	..	..	..	9	18.0	..	3	4.3	..	7	10.6	..	4	6.5	..			
<i>Very much</i>	..	..	..	2	4.0	..	4	5.7	..	2	3.0	..	4	6.5	..			
Sexual/vaginal functioning EORTC QLQ-CX24 vaginal shortness																		
Intervention																	1.18(8)	0.99
<i>Not at all</i>	..	..	..	24	46.2	..	41	53.9	..	42	54.5	..	40	57.1	..			
<i>A little</i>	..	..	..	21	40.4	..	22	28.9	..	20	26.0	..	21	30.0	..			
<i>Quite a bit</i>	..	..	..	3	5.8	..	10	13.2	..	11	14.3	..	7	10.0	..			
<i>Very much</i>	..	..	..	4	7.7	..	3	3.9	..	4	5.2	..	2	2.9	..			
Care-as-usual																		
<i>Not at all</i>	..	..	..	23	46.0	..	35	50.0	..	29	43.9	..	34	54.8	..			
<i>A little</i>	..	..	..	21	42.0	..	27	38.6	..	28	42.4	..	20	32.3	..			
<i>Quite a bit</i>	..	..	..	4	8.0	..	8	11.4	..	8	12.1	..	4	6.5	..			
<i>Very much</i>	..	..	..	2	4.0	..	0	0	..	1	1.5	..	4	6.5	..			
Sexual/vaginal functioning EORTC QLQ-CX24 vaginal tightness																		
Intervention																	3.23(8)	0.92
<i>Not at all</i>	..	..	..	22	42.3	..	47	61.8	..	54	70.1	..	51	72.9	..			
<i>A little</i>	..	..	..	19	36.5	..	24	31.6	..	14	18.2	..	14	20.0	..			
<i>Quite a bit</i>	..	..	..	7	13.5	..	5	6.6	..	8	10.4	..	5	7.1	..			
<i>Very much</i>	..	..	..	4	7.7	..	0	0	..	1	1.3	..	0	0	..			
Care-as-usual																		
<i>Not at all</i>	..	..	..	25	50.0	..	33	47.1	..	38	57.6	..	39	62.9	..			
<i>A little</i>	..	..	..	22	44.0	..	28	40.0	..	20	30.3	..	16	25.8	..			
<i>Quite a bit</i>	..	..	..	1	2.0	..	7	10.0	..	8	12.1	..	4	6.5	..			
<i>Very much</i>	..	..	..	2	4.0	..	2	2.9	..	0	0	..	3	4.8	..			

**Supplementary appendix 3** *Continued*

Outcome measure (range score)	Assessment															GLMM outcomes	
	T1			T2			T3			T4			T5			LRT(df)	P (overall model)
	N	M/%	SD	N	M/%	SD	N	M/%	SD	N	M/%	SD	N	M/%	SD		
Sexual/vaginal functioning																	
EORTC QLQ-CX24																	
Pain during intercourse																	
Intervention																1-24(8)	0-99
Not at all	..	..	..	18	34.6	..	31	40.8	..	34	44.2	..	37	52.9	..		
A little	..	..	..	29	55.8	..	38	50.0	..	35	45.5	..	27	38.6	..		
Quite a bit	..	..	..	4	7.7	..	6	7.9	..	8	10.4	..	6	8.6	..		
Very much	..	..	..	1	1.9	..	1	1.3	..	0	0	..	0	0	..		
Care-as-usual																	
Not at all	..	..	..	18	36.0	..	27	38.6	..	26	39.4	..	37	59.7	..		
A little	..	..	..	28	56.0	..	38	54.3	..	35	53.0	..	21	33.9	..		
Quite a bit	..	..	..	1	2.0	..	4	5.7	..	5	7.6	..	4	6.5	..		
Very much	..	..	..	3	6.0	..	1	1.4	..	0	0	..	0	0	..		
Sexual worry																	
EORTC QLQ-CX24 (0-100)																2-99(8)	0-94
Intervention	..	..	..	107	39.25	32.96	105	26.98	28.53	98	21.43	27.60	94	22.34	29.89		
Care-as-usual	..	..	..	109	37.00	32.18	106	25.47	25.43	98	24.15	30.57	87	19.92	28.96		
Sexual activity																	
EORTC QLQ-CX24 (0-100)																8-89(8)	0-35
Intervention	..	..	..	107	21.18	24.40	105	33.97	27.34	98	39.80	26.93	94	36.17	26.62		
Care-as-usual	..	..	..	109	22.94	29.29	106	30.82	27.87	98	30.95	27.18	87	34.87	28.26		
Sexual enjoyment																	
EORTC QLQ-CX24 (0-100)																11-58(8)	0-17
Intervention	..	..	..	52	58.97	26.09	76	59.65	29.47	77	62.77	24.76	70	62.38	28.33		
Care-as-usual	..	..	..	50	60.67	29.11	70	62.38	27.76	66	60.10	23.55	62	63.98	27.86		
Sexual interest																	
EORTC QLQ-EN24 (0-100)																4-2(8)	0-84
Intervention	..	..	..	107	30.84	27.36	105	34.92	27.50	98	38.78	27.78	94	34.04	29.32		
Care-as-usual	..	..	..	109	30.28	25.88	106	34.91	27.36	98	35.71	24.99	87	34.48	28.05		
Symptom experience																	
EORTC QLQ-CX24 (0-100)																3-01(8)	0-93
Intervention	..	..	..	107	15.89	10.55	105	13.45	8.82	98	14.13	9.63	94	13.38	10.10		
Care-as-usual	..	..	..	109	16.51	10.75	106	14.47	11.12	97	13.93	10.04	87	13.27	9.97		
Body image																	
EORTC QLQ-CX24 (0-100)																4-17(8)	0-84
Intervention	..	..	..	107	31.67	27.59	105	27.41	27.99	98	27.55	27.60	94	29.55	28.25		
Care-as-usual	..	..	..	109	29.46	26.47	104	28.95	26.02	98	27.89	25.04	87	26.44	24.80		



**Supplementary appendix 3** *Continued*

Outcome measure (range score)	Assessment															GLMM outcomes	
	T1			T2			T3			T4			T5			LRT(df)	P (overall model)
	N	M/%	SD	N	M/%	SD	N	M/%	SD	N	M/%	SD	N	M/%	SD		
Lymphedema																	
EORTC QLQ-CX24 (0-100)																6.16(8)	0.63
Intervention	..	..	..	107	11.22	21.45	106	11.32	21.52	98	14.97	26.70	94	13.83	23.14		
Care-as-usual	..	..	..	109	8.26	19.85	106	11.01	23.33	98	10.88	21.29	87	15.33	27.28		
Peripheral neuropathy																	
EORTC QLQ-CX24 (0-100)																2.68(6)	0.85
Intervention	..	..	..	107	11.84	20.09	106	16.67	26.53	98	15.99	24.51	94	17.02	25.28		
Care-as-usual	..	..	..	109	10.70	19.71	106	14.78	26.46	98	14.63	25.80	87	15.33	24.80		
Menopausal symptoms																	
EORTC QLQ-CX24 (0-100)																4.27(8)	0.83
Intervention	..	..	..	107	36.76	32.68	106	37.11	32.31	98	32.65	33.15	94	30.85	30.23		
Care-as-usual	..	..	..	109	31.19	31.84	106	30.82	33.40	98	28.91	30.13	87	23.37	28.36		
Urological symptoms																	
EORTC QLQ-CX24 (0-100)																3.32(8)	0.91
Intervention	..	..	..	107	18.77	18.28	105	13.41	14.36	98	15.14	15.48	94	13.21	12.78		
Care-as-usual	..	..	..	109	17.74	15.92	106	15.17	16.34	98	15.05	14.88	87	14.56	14.45		
Gastrointestinal symptoms																	
EORTC QLQ-CX24 (0-100)																9.28(8)	0.32
Intervention	..	..	..	107	10.67	10.60	106	12.81	13.67	98	12.50	13.18	94	12.59	13.54		
Care-as-usual	..	..	..	109	13.91	14.35	106	13.13	14.36	98	14.20	14.86	87	11.59	12.48		
Fear of sexuality - FSQ																	
fear of non-penetration sexual activity (0-20)																7.19(8)	0.51
Intervention	..	..	..	107	4.33	4.10	106	3.56	3.94	98	3.58	4.39	94	4.11	4.73		
Care-as-usual	..	..	..	109	3.83	4.10	106	3.40	3.83	98	3.30	3.80	87	3.32	4.30		
Fear of sexuality - FSQ																	
fear of coitus/vaginal penetration (0-12)																2.41(8)	0.97
Intervention	..	..	..	107	1.65	2.52	106	1.65	2.26	98	1.45	2.16	94	1.90	2.61		
Care-as-usual	..	..	..	109	1.39	2.32	106	1.69	2.81	98	1.43	2.28	87	1.66	2.59		
Relationship dissatisfaction																	
MMQ Marital scale																4.79(8)	0.78
Intervention	..	..	..	90	10.06	11.53	89	9.97	11.57	83	10.29	11.74	78	11.45	13.30		
Care-as-usual	..	..	..	84	11.76	15.35	80	10.75	12.44	72	10.08	9.58	66	10.85	11.16		

**Supplementary appendix 3** *Continued*

Outcome measure (range score)	Assessment															GLMM outcomes	
	T1			T2			T3			T4			T5			LRT(df)	P (overall model)
	N	M/%	SD	N	M/%	SD	N	M/%	SD	N	M/%	SD	N	M/%	SD		
Psychological distress HADS Total (0-42)	..	..	..	107	9.95	7.30	105	9.87	7.14	98	9.46	7.33	94	8.93	7.74	5.87(8)	0.66
Intervention	..	..	..	107	9.93	7.65	106	9.80	7.32	98	10.00	6.83	87	9.32	6.63		
Care-as-usual	..	..	..	107	9.93	7.65	106	9.80	7.32	98	10.00	6.83	87	9.32	6.63		
Psychological distress HADS depression (0-21)	..	..	..	107	4.22	3.68	105	4.13	3.89	98	3.87	3.62	94	3.47	3.79	5.96(8)	0.65
Intervention	..	..	..	107	4.36	4.03	106	4.01	3.86	98	4.21	3.64	87	3.41	3.36		
Care-as-usual	..	..	..	107	4.36	4.03	106	4.01	3.86	98	4.21	3.64	87	3.41	3.36		
Psychological distress HADS anxiety (0-21)	..	..	..	107	5.74	4.29	105	5.73	3.89	98	5.59	4.36	94	5.38	4.48	7.48(8)	0.49
Intervention	..	..	..	107	5.57	4.34	106	5.79	4.27	98	5.79	4.07	87	5.91	4.03		
Care-as-usual	..	..	..	107	5.57	4.34	106	5.79	4.27	98	5.79	4.07	87	5.91	4.03		
Physical function EORTC QLQ-C30 (0-100)	..	..	..	107	82.12	16.60	105	85.91	16.39	98	88.57	13.02	94	92.27	10.81	8.28(8)	0.41
Intervention	..	..	..	109	81.22	16.89	106	86.04	14.59	98	88.10	13.17	86	91.32	11.57		
Care-as-usual	..	..	..	109	81.22	16.89	106	86.04	14.59	98	88.10	13.17	86	91.32	11.57		
Role function EORTC QLQ-C30 (0-100)	..	..	..	107	66.04	30.45	106	71.23	27.65	98	72.79	29.05	94	80.50	24.15	17.12(8)	0.03*
Intervention	..	..	..	109	66.67	25.36	106	69.81	25.73	98	75.17	23.96	87	82.95	23.29		
Care-as-usual	..	..	..	109	66.67	25.36	106	69.81	25.73	98	75.17	23.96	87	82.95	23.29		
Emotional function EORTC QLQ-C30 (0-100)	..	..	..	107	70.25	20.92	106	71.78	20.88	98	71.51	21.37	94	73.49	23.02	9.16(8)	0.33
Intervention	..	..	..	109	66.67	23.07	106	67.37	23.60	98	67.18	23.32	87	73.85	19.70		
Care-as-usual	..	..	..	109	66.67	23.07	106	67.37	23.60	98	67.18	23.32	87	73.85	19.70		
Cognitive function EORTC QLQ-C30 (0-100)	..	..	..	107	71.18	23.52	106	74.06	20.97	98	68.71	25.02	94	72.87	24.32	11.47(8)	0.18
Intervention	..	..	..	109	68.65	24.19	106	70.44	23.15	98	72.11	25.19	87	76.05	23.80		
Care-as-usual	..	..	..	109	68.65	24.19	106	70.44	23.15	98	72.11	25.19	87	76.05	23.80		
Social function EORTC QLQ-C30 (0-100)	..	..	..	107	67.76	27.31	106	73.74	25.09	98	76.53	24.27	94	83.51	19.48	9.7(8)	0.29
Intervention	..	..	..	109	68.20	26.11	106	73.11	24.08	98	77.38	20.20	87	82.38	20.70		
Care-as-usual	..	..	..	109	68.20	26.11	106	73.11	24.08	98	77.38	20.20	87	82.38	20.70		
Fatigue EORTC QLQ-C30 (0-100)	..	..	..	107	41.85	22.41	106	36.16	23.36	98	36.40	20.54	94	30.14	23.98	22.63(8)	0.004*
Intervention	..	..	..	108	44.65	23.63	105	40.42	23.22	98	36.84	22.82	87	28.86	23.57		
Care-as-usual	..	..	..	108	44.65	23.63	105	40.42	23.22	98	36.84	22.82	87	28.86	23.57		

**Supplementary appendix 3** *Continued*

Outcome measure (range score)	Assessment															GLMM outcomes	
	T1			T2			T3			T4			T5			LRT(df)	P (overall model)
	N	M/%	SD	N	M/%	SD	N	M/%	SD	N	M/%	SD	N	M/%	SD		
Nausea/vomiting																	
EORTC QLQ-C30 (0-100)																6.45(6)	0.38
Intervention	..	..	..	107	5.61	10.97	106	7.55	16.92	97	7.05	14.60	94	6.74	13.23		
Care-as-usual	..	..	..	109	8.26	12.75	106	5.35	14.47	98	5.61	10.42	87	4.02	8.79		
Pain																	
EORTC QLQ-C30 (0-100)																6.34(8)	0.61
Intervention	..	..	..	107	20.09	20.57	106	19.18	21.18	97	20.96	23.97	94	16.67	22.0		
Care-as-usual	..	..	..	109	19.88	23.18	106	19.81	24.03	98	20.41	23.88	87	14.18	19.94		
Dyspnoea																	
EORTC QLQ-C30 (0-100)																3.23(8)	0.92
Intervention	..	..	..	107	17.45	23.50	106	11.95	17.33	98	9.18	18.40	94	10.28	20.75		
Care-as-usual	..	..	..	109	16.82	21.58	106	14.47	18.98	98	11.22	21.38	87	7.66	15.83		
Sleep disturbance																	
EORTC QLQ-C30 (0-100)																9.71(8)	0.29
Intervention	..	..	..	107	36.14	29.0	106	32.39	31.02	98	31.63	29.65	94	30.14	31.71		
Care-as-usual	..	..	..	109	30.89	29.64	106	28.62	30.32	98	29.59	26.17	87	27.20	27.15		
Appetite loss																	
EORTC QLQ-C30 (0-100)																1.82(6)	0.94
Intervention	..	..	..	107	9.66	15.87	106	10.06	19.61	98	8.84	18.88	94	6.74	16.0		
Care-as-usual	..	..	..	109	13.76	22.32	106	7.86	17.55	98	7.48	16.25	87	6.13	15.69		
Constipation																	
EORTC QLQ-C30 (0-100)																1.53(8)	0.99
Intervention	..	..	..	107	10.28	18.55	106	10.06	18.50	97	12.72	21.75	94	10.28	18.31		
Care-as-usual	..	..	..	109	10.40	22.54	106	6.60	15.55	98	11.57	24.92	87	7.28	18.63		
Diarrhoea																	
EORTC QLQ-C30 (0-100)																3.51(8)	0.90
Intervention	..	..	..	107	13.08	19.83	106	14.78	22.58	98	15.31	23.04	94	11.35	18.65		
Care-as-usual	..	..	..	109	19.57	24.52	106	17.61	26.11	98	18.37	23.02	87	12.64	19.85		
Financial impact																	
EORTC QLQ-C30 (0-100)																2.9(8)	0.94
Intervention	..	..	..	107	12.46	23.58	106	13.21	23.76	98	11.91	20.45	94	11.35	21.06		
Care-as-usual	..	..	..	109	15.60	25.49	106	11.01	22.41	98	10.20	20.54	87	14.18	25.74		
Global QoL																	
EORTC QLQ-C30 (0-100)																7.2(8)	0.51
Intervention	..	..	..	107	64.95	16.42	106	69.18	18.59	98	69.98	16.91	94	73.49	16.71		
Care-as-usual	..	..	..	109	67.05	17.98	106	68.24	17.06	98	69.05	18.27	87	75.58	15.29		

**Supplementary appendix 3** *Continued*

Outcome measure (range score)	Assessment															GLMM outcomes			
	T1			T2			T3			T4			T5			LRT(df)	P (overall model)		
	N	M/%	SD	N	M/%	SD	N	M/%	SD	N	M/%	SD	N	M/%	SD				
Gynaecological cancer treatment related stress																6-03(8)	0-64		
IES Total (0-75)																			
Intervention	..	..	..	107	24-09	16-61	105	20-05	15-83	98	19-12	16-46	94	17-49	16-24				
Care-as-usual	..	..	..	107	24-24	17-33	106	21-65	16-06	98	20-95	15-93	87	18-66	16-10				
<b>Physician-assessed</b>																			
Stenosis (shortening/tightening) CTCAE																8-83(5)	0-12		
Intervention																			
Grade 0	96	90-6	..	75	83-3	..	62	70-5	..	57	64-0	..	56	63-6	..				
Grade 1	8	7-5	..	11	12-2	..	20	22-7	..	26	29-2	..	21	23-9	..				
Grade 2	1	0-9	..	4	4-4	..	5	5-7	..	2	2-2	..	10	11-4	..				
Grade 3	1	0-9	..	0	0	..	1	1-1	..	4	4-5	..	1	1-1	..				
Care-as-usual																			
Grade 0	110	94-0	..	82	79-6	..	77	78-6	..	66	67-3	..	56	65-1	..				
Grade 1	4	3-4	..	19	18-4	..	14	14-3	..	22	22-4	..	20	23-3	..				
Grade 2	3	2-6	..	2	1-9	..	4	4-1	..	8	8-2	..	8	9-3	..				
Grade 3	0	0	..	0	0	..	3	3-1	..	2	2-0	..	2	2-3	..				
Dryness CTCAE																4-64(5)	0-46		
Intervention																			
Grade 0	99	96-1	..	77	85-6	..	57	65-5	..	59	68-6	..	60	70-6	..				
Grade 1	2	1-9	..	12	13-3	..	20	23-0	..	17	19-8	..	18	21-2	..				
Grade 2	1	1-0	..	1	1-1	..	10	11-5	..	8	9-3	..	6	7-1	..				
Grade 3	1	1-0	..	0	0	..	0	0	..	2	2-3	..	1	1-2	..				
Care-as-usual																			
Grade 0	103	92-8	..	80	78-4	..	73	74-5	..	69	72-6	..	55	67-1	..				
Grade 1	4	3-6	..	19	18-6	..	24	24-5	..	24	25-3	..	26	31-7	..				
Grade 2	4	3-6	..	2	2-0	..	1	1-0	..	2	2-1	..	1	1-2	..				
Grade 3	0	0	..	1	1-0	..	0	0	..	0	0	..	0	0	..				
Bleeding CTCAE																7-6(5)	0-18		
Intervention																			
Grade 0	47	42-3	..	94	87-0	..	81	86-2	..	76	82-6	..	78	83-0	..				
Grade 1	32	28-8	..	11	10-2	..	13	13-8	..	15	16-3	..	14	14-9	..				
Grade 2	26	23-4	..	3	2-8	..	0	0	..	1	1-1	..	2	2-1	..				
Grade 3	6	5-4	..	0	0	..	0	0	..	0	0	..	0	0	..				
Care-as-usual																			
Grade 0	51	43-6	..	102	91-1	..	88	81-5	..	78	77-2	..	72	80-0	..				
Grade 1	32	27-4	..	10	8-9	..	19	17-6	..	22	21-8	..	17	18-9	..				
Grade 2	31	26-5	..	0	0	..	1	0-9	..	1	1-0	..	1	1-1	..				
Grade 3	3	2-6	..	0	0	..	0	0	..	0	0	..	0	0	..				

**Supplementary appendix 3** *Continued*

Outcome measure (range score)	Assessment															GLMM outcomes	
	T1			T2			T3			T4			T5			LRT(df)	P (overall model)
	N	M/ %	SD	N	M/ %	SD	N	M/ %	SD	N	M/ %	SD	N	M/ %	SD		
<b>Mucositis CTCAE</b>																	
Intervention																11.04(5)	0.05*
Grade 0	104	97.2	..	51	53.1	..	68	74.7	..	74	86.0	..	72	80.9	..		
Grade 1	3	2.8	..	41	42.7	..	21	23.1	..	10	11.6	..	13	14.6	..		
Grade 2	0	0	..	4	4.2	..	2	2.2	..	1	1.2	..	3	3.4	..		
Grade 3	0	0	..	0	0	..	0	0	..	1	1.2	..	1	1.1	..		
Grade 4	0	0	..	0	0	..	0	0	..	0	0	..	0	0	..		
Care-as-usual																	
Grade 0	111	95.7	..	54	50.9	..	68	71.6	..	81	84.4	..	70	82.4	..		
Grade 1	4	3.4	..	46	43.4	..	21	22.1	..	12	12.5	..	13	15.3	..		
Grade 2	1	0.9	..	5	4.7	..	2	2.1	..	2	2.1	..	2	2.4	..		
Grade 3	0	0	..	1	0.9	..	3	3.2	..	1	1.0	..	0	0	..		
Grade 4	0	0	..	0	0	..	1	1.1	..	0	0	..	0	0	..		
<b>Discharge CTCAE</b>																	
Intervention																1.65(5)	0.90
Grade 0	73	67.0	..	57	53.8	..	60	64.5	..	66	73.3	..	65	70.7	..		
Grade 1	23	21.1	..	45	42.5	..	30	32.3	..	23	25.6	..	24	26.1	..		
Grade 2	13	11.9	..	4	3.8	..	3	3.2	..	1	1.1	..	3	3.3	..		
Grade 3	0	0	..	0	0	..	0	0	..	0	0	..	0	0	..		
Care-as-usual																	
Grade 0	70	61.4	..	56	50.5	..	66	63.5	..	69	70.4	..	62	68.9	..		
Grade 1	33	28.9	..	43	38.7	..	29	27.9	..	20	20.4	..	27	30.0	..		
Grade 2	11	9.6	..	12	10.8	..	9	8.7	..	9	9.2	..	1	1.1	..		
Grade 3	0	0	..	0	0	..	0	0	..	0	0	..	0	0	..		
<b>Fibrosis CTCAE</b>																	
Intervention																3.03(5)	0.70
Grade 0	104	98.1	..	93	97.9	..	74	85.1	..	66	77.6	..	58	67.4	..		
Grade 1	2	1.9	..	2	2.1	..	13	14.9	..	18	21.2	..	25	29.1	..		
Grade 2	0	0	..	0	0	..	0	0	..	1	1.2	..	2	2.3	..		
Grade 3	0	0	..	0	0	..	0	0	..	0	0	..	1	1.2	..		
Care-as-usual																	
Grade 0	111	96.5	..	88	88.9	..	79	85.9	..	77	80.2	..	60	72.3	..		
Grade 1	3	2.6	..	11	11.1	..	13	14.1	..	15	15.6	..	22	26.5	..		
Grade 2	1	0.9	..	0	0	..	0	0	..	3	3.1	..	1	1.2	..		
Grade 3	0	0	..	0	0	..	0	0	..	1	1.0	..	0	0	..		

**Supplementary appendix 3** *Continued*






Outcome measure (range score)	Assessment															GLMM outcomes		
	T1			T2			T3			T4			T5			LRT(df)	P (overall model)	
	N	M/ %	SD	N	M/ %	SD	N	M/ %	SD	N	M/ %	SD	N	M/ %	SD			
<b>Atrophy/telangiectasia CTCAE</b>																		
Intervention																	6.29(4)	0.18
Grade 0	103	97.2	..	81	87.1	..	65	73.9	..	51	63.0	..	42	49.4	..			
Grade 1	2	1.9	..	12	12.9	..	23	26.1	..	29	35.8	..	35	41.2	..			
Grade 2	1	0.9	..	0	0	..	0	0	..	1	1.2	..	6	7.1	..			
Grade 3	0	0	..	0	0	..	0	0	..	0	0	..	1	1.2	..			
Grade 4	0	0	..	0	0	..	0	0	..	0	0	..	1	1.2	..			
Care-as-usual																		
Grade 0	115	100.0	..	87	87.0	..	68	76.4	..	64	67.4	..	42	52.5	..			
Grade 1	0	0	..	13	13.0	..	20	22.5	..	28	29.5	..	36	45.0	..			
Grade 2	0	0	..	0	0	..	1	1.1	..	2	2.1	..	1	1.3	..			
Grade 3	0	0	..	0	0	..	0	0	..	1	1.1	..	1	1.3	..			
Grade 4	0	0	..	0	0	..	0	0	..	0	0	..	0	0	..			
<b>Pain CTCAE</b>																		
Intervention																	1.53(5)	0.91
Grade 0	92	87.6	..	91	90.1	..	87	88.8	..	82	91.1	..	80	88.9	..			
Grade 1	11	10.5	..	8	7.9	..	11	11.2	..	7	7.8	..	5	5.6	..			
Grade 2	2	1.9	..	2	2.0	..	0	0	..	1	1.1	..	5	5.6	..			
Grade 3	0	0	..	0	0	..	0	0	..	0	0	..	0	0	..			
Care-as-usual																		
Grade 0	107	92.2	..	90	80.4	..	94	87.9	..	87	88.8	..	80	90.9	..			
Grade 1	7	6.0	..	20	17.9	..	9	8.4	..	8	8.2	..	8	9.1	..			
Grade 2	2	1.7	..	2	1.8	..	3	2.8	..	2	2.0	..	0	0	..			
Grade 3	0	0	..	0	0	..	1	0.9	..	1	1.0	..	0	0	..			
<b>Dyspareunia CTCAE</b>																		
Intervention																	1.37(5)	0.93
Grade 0	74	91.4	..	45	80.4	..	45	62.5	..	50	61.7	..	54	64.3	..			
Grade 1	3	3.7	..	9	16.1	..	21	29.2	..	24	29.6	..	24	28.6	..			
Grade 2	2	2.5	..	2	3.6	..	5	6.9	..	5	6.2	..	4	4.8	..			
Grade 3	2	2.5	..	0	0	..	1	1.4	..	2	2.5	..	2	2.4	..			
Care-as-usual																		
Grade 0	73	84.9	..	34	64.2	..	49	63.6	..	50	64.9	..	50	71.4	..			
Grade 1	10	11.6	..	15	28.3	..	18	23.4	..	17	22.1	..	14	20.0	..			
Grade 2	3	3.5	..	3	5.7	..	9	11.7	..	8	10.4	..	5	7.1	..			
Grade 3	0	0	..	1	1.9	..	1	1.3	..	2	2.6	..	1	1.4	..			

*Note.* CTCAE = Common Terminology Criteria for Adverse Events; df = degrees of freedom; EORTC QLQ-C30 = European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30; EORTC QLQ-CX24 = European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gynaecological Cancer Module; EORTC QLQ-EN24 = European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Endometrial Cancer Module; FSQS = Female Sexual Distress Scale; FSFI = Female Sexual Function Index; FSQ = Fear of Sexuality Questionnaire; GLMM = Generalized Linear Mixed effects Model; HADS = Hospital Anxiety and Depression Scale; IES = Impact of Event Scale; IQR = interquartile range; M = mean; Md = median; MMQ = Maudsley Marital Questionnaire; N = observed number of women at the specific timepoint; QoL = Quality of Life; SD = standard deviation.

\*p < 0.05.



**Supplementary appendix 4** Physician-reported clinical measurements on single item level over time. The proportion of women is shown in percentages. BM = baseline measurement; CTCAE = Common Terminology Criteria for Adverse Events; M = months; N = number of women at risk at the specific timepoint; O = observed number of women at the specific timepoint.



**Supplementary appendix 5** Patient-reported vaginal functioning problems on single item level over time. The proportion of women is shown in percentages. Figure I and IV only includes sexually active women. EORTC QLQ-CX24 = European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gynaecological Cancer Module; EORTC QLQ-EN24 = European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Endometrial Cancer Module; M = months; N = number of women at risk at the specific timepoint; n = number of sexually active women at risk at the specific timepoint according to EORTC QLQ-CX24 item 19; O = observed number of women at the specific timepoint.



**Supplementary appendix 6 The prevalence of women scoring at a clinical level on sexual functioning, sexual distress, relationship dissatisfaction, and psychological distress**

	N	n cut-off*	% cut-off*
<b>Primary Outcome</b>			
FSFItotal BM			
Intervention (total group)	112	33	29.5
Care-as-usual (total group)	117	29	24.8
Sexually active	185	47	25.4
Not sexually active	42	14	33.3
Sexual intercourse	192	33	17.2
No sexual intercourse	35	28	80.0
FSFItotal 1M			
Intervention (total group)	108	80	74.1
Care-as-usual (total group)	110	82	74.5
Sexually active	128	79	61.7
Not sexually active	90	83	92.2
Sexual intercourse	84	38	45.2
No sexual intercourse	133	123	92.5
FSFItotal 3M			
Intervention (total group)	106	67	63.2
Care-as-usual (total group)	106	65	61.3
Sexually active	139	78	56.1
Not sexually active	73	54	74.0
Sexual intercourse	138	67	48.6
No sexual intercourse	74	65	87.8
FSFItotal 6M			
Intervention (total group)	98	49	50.0
Care-as-usual (total group)	98	54	55.1
Sexually active	128	59	46.1
Not sexually active	68	44	64.7
Sexual intercourse	134	48	35.8
No sexual intercourse	62	55	88.7
FSFItotal 12M			
Intervention (total group)	94	53	56.4
Care-as-usual (total group)	87	47	54.0
Sexually active	127	59	46.5
Not sexually active	54	41	75.9
Sexual intercourse	121	45	37.2
No sexual intercourse	60	55	91.7
<b>Secondary Outcomes</b>			
FSDStotal BM			
Intervention	112	29	25.9
Care-as-usual	117	30	25.6
FSDStotal 1M			
Intervention	107	54	50.5
Care-as-usual	110	49	44.5
FSDStotal 3M			
Intervention	106	49	46.2
Care-as-usual	106	45	42.5
FSDStotal 6M			
Intervention	98	43	43.9
Care-as-usual	98	46	46.9
FSDStotal 12M			
Intervention	94	42	44.7
Care-as-usual	87	40	46.0
MMQtotal 1M			
Intervention	90	13	14.4
Care-as-usual	84	16	19.0
MMQtotal 3M			
Intervention	89	16	18.0
Care-as-usual	80	15	18.8

**Supplementary appendix 6 Continued**

MMQtotal 6M			
Intervention	83	17	20.5
Care-as-usual	72	11	15.3
MMQtotal 12M			
Intervention	78	15	19.2
Care-as-usual	66	13	19.7
HADStotal 1M			
Intervention	107	32	29.9
Care-as-usual	107	33	30.8
HADStotal 3M			
Intervention	105	33	31.4
Care-as-usual	106	27	25.5
HADStotal 6M			
Intervention	98	27	27.6
Care-as-usual	98	31	31.6
HADStotal 12M			
Intervention	94	21	22.3
Care-as-usual	87	21	24.1
HADS depression 1M			
Intervention	107	28	26.2
Care-as-usual	107	28	26.2
HADS depression 3M			
Intervention	105	25	23.8
Care-as-usual	106	20	18.9
HADS depression 6M			
Intervention	98	22	22.4
Care-as-usual	98	21	21.4
HADS depression 12M			
Intervention	94	21	22.3
Care-as-usual	87	16	18.4
HADS anxiety 1M			
Intervention	107	41	38.3
Care-as-usual	107	38	35.5
HADS anxiety 3M			
Intervention	105	43	41.0
Care-as-usual	106	41	38.7
HADS anxiety 6M			
Intervention	98	37	37.8
Care-as-usual	98	35	35.7
HADS anxiety 12M			
Intervention	94	31	33.0
Care-as-usual	87	36	41.4

*Note.* BM = baseline measurement; FSFI = Female Sexual Function Index; FSDS = Female Sexual Distress Scale; HADS = Hospital Anxiety and Depression Scale; M = months; MMQ = Maudsley Marital Questionnaire; N = observed number of women at the specific timepoint (for the MMQ, this number only includes women with a partner).

\* = women that scored above/below the clinical cut-off point.